Art. -Nr.: HY-B0580

Ketorolac

(Synonyms: RS37619)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC₅₀s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.87%
CAS. Nr.: 74103-06-3
Formel: C₁₅H₁₃NO₃
Molecular Weight:255.27

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ketorolac Chemical Structure

CAS. Nr.: 74103-06-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

COX-1

20 nM (IC₅₀)

COX-2

120 nM (IC₅₀)

DDX3

Alle COX Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	13 μM Compound: Toradol	Inhibition of PAK1/COX2 in human A549 cells harboring Ki-RAS mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Inhibition of PAK1/COX2 in human A549 cells harboring Ki-RAS mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 27889630]
A549	IC₅₀	36 μM Compound: Toradol	Inhibition of PAK1 in human A549 cells using myelin basic protein as substrate preincubated for 24 hrs followed by PAK1 immunoprecipation and substrate addition measured after 60 mins by ATP-Glo kinase assay Inhibition of PAK1 in human A549 cells using myelin basic protein as substrate preincubated for 24 hrs followed by PAK1 immunoprecipation and substrate addition measured after 60 mins by ATP-Glo kinase assay	[PMID: 27889630]
B16-F10	IC₅₀	30 μM Compound: Toradol	Cytotoxicity against PAK1-independent mouse B16F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against PAK1-independent mouse B16F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 27889630]

In Vitro

Ketorolac (RS37619) salt (0-30 μM; 48 h) effectively kills the oral cancer cells^[4].
Ketorolac salt (0-5 μM; 48 h) inhibits the expression of DDX3 protein, and induces apoptosis in H357 cells^[4].
Ketorolac salt (0-2.5 μM; 0-16 h) inhibits the proliferation of oral cancer cells^[4].
Ketorolac salt (0-50 μM) directly interacts with DDX3 and inhibits the ATPase activity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

HOK, SCC4, SCC9 and H357 cells
Concentration:

0-30 μM
Incubation Time:

48 h
Result:

Showed inhibition with IC₅₀s of 2.6, 7.1 and 8.1 μM against H357, SCC4 and SCC9 cells, respectively. And the normal HOK cell line did not show any cell death effect.

Cell Proliferation Assay^[4]

Cell Line:

H357
Concentration:

0.5, 1.0, 1.5, 2.0 and 2.5 μM
Incubation Time:

0, 8 and 16 h
Result:

Inhibited the proliferation.

Western Blot Analysis^[4]

Cell Line:

H357
Concentration:

1, 2.5 and 5 μM
Incubation Time:

48 h
Result:

Significantly reduced DDX3 protein expression levels, but not completely ablated as compared to DMSO treated cells. Up regulated the expression of E-cadherin.

Apoptosis Analysis^[4]

Cell Line:

H357
Concentration:

2.5 and 5 μM
Incubation Time:

48 h
Result:

Induced apoptosis.

In Vivo

Ketorolac (RS37619) (0.4% ketorolac tromethamine ophthalmic solution) shows powerful ocular anti-inflammatory activities in rabbits^[1].
Ketorolac (4 mg/kg/day, p.o.; 2 weeks) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats^[2].
Ketorolac (60 μg; intrathecal injection; once) attenuates the damage caused by spinal cord ischemia in rats^[3].
Ketorolac salt (20 and 30 mg/kg; i.p.; two times in a week for 3 weeks) reduces oral carcinogenesis in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

New Zealand White rabbits (2.0–2.7 kg), LPS endotoxin-induced ocular inflammation^[1]
Dosage:

50 μL ketorolac tromethamine ophthalmic solution 0.4%
Administration:

In eyes, twice, 2 hours and 1 hour before LPS challenge
Result:

Resulted in a nearly complete inhibition (98.7%) of LPS endotoxin-induced increases in FITC (fluorescein isothiocyanate)-dextran in the anterior chamber, and resulted in a nearly complete inhibition (97.5%) of LPS endotoxin-induced increases in aqueous PGE₂ concentrations in the aqueous humor.

Animal Model:

Male Wistar rats (400–450 g), spinal cord ischemia model^[3]
Dosage:

30 and 60 μg
Administration:

Intrathecal injection, 1 h before the ischemia induction for once
Result:

Significantly reduced the motor disturbances and improved the survival rate at 60 μg.

Animal Model:

Significantly reduced the motor disturbances and improved the survival rate at 60 μg.
Dosage:

20 mg/kg and 30 mg/kg
Administration:

IP injection, two times in a week for 3 weeks
Result:

Decreased tumor burden, reduced expression of DDX3 and anti-apoptotic proteins (Bcl-2 and Mcl-1).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 74103-06-3
Appearance Solid
Molecular Weight 255.27
Formel C₁₅H₁₃NO₃
Color Light yellow to yellow
SMILES

O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)O
Synonyms

RS37619
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (3)

All

Sort by:

Journal Impact Factor

Eur J Med Chem

Innovative medicinal chemistry strategies for enhancing drug solubility. [Abstract]

2024 Dec 5:279:116842. PMID: 39260319
BMC Anesthesiol

Inflammation and macrophage infiltration exacerbate adult incision response by early life injury. [Abstract]

2025 Apr 10;25(1):165. PMID: 40211125
Immunobiology

Effect of perioperative analgesia on immunity in lung cancer. [Abstract]

2025 Mar;230(2):152867. PMID: 39847998

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 200 mg/mL (783.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9174 mL

19.5871 mL

39.1742 mL

5 mM

0.7835 mL

3.9174 mL

7.8348 mL

10 mM

0.3917 mL

1.9587 mL

3.9174 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [Content Brief]

[2]. Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18(6):630-4. [Content Brief]

[3]. Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100(4):1134-9. [Content Brief]

[4]. Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9174 mL	19.5871 mL	39.1742 mL	97.9355 mL
	5 mM	0.7835 mL	3.9174 mL	7.8348 mL	19.5871 mL
	10 mM	0.3917 mL	1.9587 mL	3.9174 mL	9.7936 mL
	15 mM	0.2612 mL	1.3058 mL	2.6116 mL	6.5290 mL
	20 mM	0.1959 mL	0.9794 mL	1.9587 mL	4.8968 mL
	25 mM	0.1567 mL	0.7835 mL	1.5670 mL	3.9174 mL
	30 mM	0.1306 mL	0.6529 mL	1.3058 mL	3.2645 mL
	40 mM	0.0979 mL	0.4897 mL	0.9794 mL	2.4484 mL
	50 mM	0.0783 mL	0.3917 mL	0.7835 mL	1.9587 mL
	60 mM	0.0653 mL	0.3265 mL	0.6529 mL	1.6323 mL
	80 mM	0.0490 mL	0.2448 mL	0.4897 mL	1.2242 mL
	100 mM	0.0392 mL	0.1959 mL	0.3917 mL	0.9794 mL

Ketorolac

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ketorolac

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Antidepressant Compound Library

Protein-protein Interaction Inhibitor Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Publications Citing Use of MedChemExpress (MCE) Ketorolac

Alle COX Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ketorolac Related Classifications

HY-B0580 Related Classifications